Surrozen, Inc. (SRZN)
NASDAQ: SRZN · Real-Time Price · USD
20.46
+2.23 (12.23%)
At close: Dec 5, 2025, 4:00 PM EST
20.76
+0.30 (1.47%)
After-hours: Dec 5, 2025, 5:48 PM EST
Surrozen Revenue
Surrozen had revenue of $983.00K in the quarter ending September 30, 2025, a decrease of -90.17%. This brings the company's revenue in the last twelve months to $3.60M, down -63.96% year-over-year. In the year 2024, Surrozen had annual revenue of $10.66M.
Revenue (ttm)
$3.60M
Revenue Growth
-63.96%
P/S Ratio
34.13
Revenue / Employee
$87,902
Employees
41
Market Cap
175.37M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SRZN News
- 11 days ago - Surrozen to Present at Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 24 days ago - Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Surrozen to Present at Upcoming Healthcare Investor Conference - GlobeNewsWire
- 3 months ago - Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Surrozen Reports Q2 Profit on Gains - The Motley Fool
- 4 months ago - Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway - GlobeNewsWire